首页  >  学科前沿 {{articleInfo.dynamicName}}  > 国际TOP10医学期刊药物治疗信息 (2024年6月)

国际TOP10医学期刊药物治疗信息 (2024年6月)

{{releTime.slice(0,10)}}     来源:药物治疗网     :     阅读量:5300

一、临床肿瘤杂志 (2024年第74卷第3期)

May/June 2024 - Volume 74 - Issue 3 (2024年5/6月第74卷第3期)
https://acsjournals.onlinelibrary.wiley.com/toc/15424863/2024/74/3

REVIEW ARTICLES 
1. 阿片类镇痛药用于伤害性癌症疼痛:一项全面综述
Opioid analgesics for nociceptive cancer pain: A comprehensive review
作者:Christina Abdel Shaheed* (University of Sydney, Australia)

二、柳叶刀 (2024年第403卷第10442-10446期)

(一)01 June 2024 - Volume 403 - Issue 104442 (2024年6月1日第403卷第10442期)
https://www.thelancet.com/journals/lancet/issue/vol403no10442/PIIS0140-6736(24)X0022-7

PERSPECTIVE(观点)
1. Ramanan Laxminarayan:寻求可持续的抗生素获取方式
Ramanan Laxminarayan: seeking sustainable access to antibiotics
作者:Udani Samarasekera

(二)08 June 2024 - Volume 403 - Issue 10443 (2024年6月8日第403卷第10443期)
https://www.thelancet.com/journals/lancet/issue/vol403no10443/PIIS0140-6736(24)X0023-9

COMMENT(评论)
1. 比麦珠单抗:双重抑制作为管理化脓性汗腺炎的一种有希望的工具
Bimekizumab: dual inhibition as a promising tool in the management of hidradenitis suppurativa
作者:Elisa Molinelli* (Polytechnic Marche University, Italy)
ARTICLES (文章)
1. BE HEARD I 和 BE HEARD II:两项针对中至重度化脓性汗腺炎患者的48周、随机、双盲、安慰剂对照、多中心3期临床试验中Bimekizumab的疗效与安全性
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
作者:Alexa B Kimball* (Harvard Medical School, USA)
SERIES (系列)
Sustainable Access to Antibiotics(抗生素的可持续获取)
1. 扩大抗生素、疫苗和诊断方法的开发与获取,以应对抗生素耐药性问题
Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance
作者:Ramanan Laxminarayan* (One Health Trust, India)
2. 确保在2024年联合国大会(UNGA)上取得有效抗生素可持续获取方面的进展:一种基于目标的方法
Ensuring progress on sustainable access to effective antibiotics at the 2024 UN General Assembly: a target-based approach
作者:Marc Mendelson* (Groote Schuur Hospital, University of Cape Town, South Africa)

(三)15 June 2024 - Volume 403 - Issue 10444 (2024年6月15日第403卷第10444期)
https://www.thelancet.com/journals/lancet/issue/vol403no10444/PIIS0140-6736(24)X0024-0

COMMENT(评论)
1. 40年后发现幽门螺杆菌:朝着消除幽门螺杆菌预防胃癌的方向
40 years after the discovery of Helicobacter pylori: towards elimination of H pylori for gastric cancer prevention
作者:Jyh-Ming Liou, Ming-Shiang Wu* (National Taiwan University College of Medicine, Taiwan, China)
ARTICLES(文章)
1. 替奈普酶与标准治疗在证实闭塞的轻微缺血性中风中的比较(TEMPO-2):一项随机、开放标签、3期优效性试验
Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial
作者:Shelagh B Coutts* (University of Calgary, Canada)

(四)22 June 2024 - Volume 403 - Issue 10445 (2024年6月22日第403卷第10445期)
https://www.thelancet.com/journals/lancet/issue/vol403no10445/PIIS0140-6736(24)X0025-2

COMMENT(评论)
1. 维姆塞替尼用于治疗腱鞘巨细胞瘤
Vimseltinib for tenosynovial giant cell tumour
作者:Hiroshi Urakawa* (Nagoya University Hospital, Japan)
2. 鼻咽癌中的免疫治疗:持续不断的成功
Immunotherapeutics in nasopharyngeal carcinoma: a relentless CONTINUUM of success
作者:Nabil F Saba* (Emory University, USA)
WORLD REPORT (国际报道)
1. 美国最高法院保护了获取堕胎药物的途径
US Supreme Court protects access to abortion medication
作者:Susan Jaffe
2. 婴儿血吸虫病治疗的挑战
Challenges for infant schistosomiasis treatment
作者:Sharmila Devi
ARTICLES(文章)
1. 维姆塞替尼与安慰剂治疗腱鞘巨细胞瘤(MOTION):一项多中心、随机、双盲、安慰剂对照的3期试验
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
作者:Hans Gelderblom* (Leiden University Medical Center, Netherlands)
2. 信迪利单抗联合诱导-同期化放疗在中国局部晚期鼻咽癌患者中的研究(CONTINUUM):一项多中心、开放标签、平行组、随机对照、3期临床试验
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial
作者:Xu Liu1, Yuan Zhang1, Kun-Yu Yang2, Ning Zhang3, Feng Jin4, Guo-Rong Zou5, Xiao-Dong Zhu6, Fang-Yun Xie1, Xiao-Yu Liang1, Jun Ma1* (1. Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, China; 2. Huazhong University of Science and Technology, China; 3. First People's Hospital of Foshan, China; 4. The Affiliated Cancer Hospital of Guizhou Medical University, China; 5. Panyu Central Hospital, China; 6. Affiliated Tumor Hospital of Guangxi Medical University, China)

(五)29 June 2024 - Volume 403 - Issue 10446 (2024年6月29日第403卷第10446期)
https://www.thelancet.com/journals/lancet/issue/vol403no10446/PIIS0140-6736(24)X0026-4

COMMENT (评论)
1. 抗菌耐药性公正过渡:为抗菌耐药性下公平可持续的未来做规划
A just transition for antimicrobial resistance: planning for an equitable and sustainable future with antimicrobial resistance
作者:AMR Working Group (London School of Hygiene & Tropical Medicine, UK)
WORLD REPORT (国际报道)
1. 在英国氨甲环酸的低使用率
Underuse of tranexamic acid in the UK
作者:Talha Burki
ARTICLES (文章)
1. [177Lu]Lu-DOTA-TATE联合长效奥曲肽与高剂量长效奥曲肽治疗新诊断的、晚期2-3级、分化良好的胃肠道胰腺神经内分泌肿瘤(NETTER-2):一项开放标签、随机、3期研究
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus highdose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
作者:Simron Singh* (University of Toronto, Sunnybrook Odette Cancer Centre, Canada)

三、新英格兰医学杂志 (2024年6月第390卷第21-24期)

(一)6 June 2024 - Volume 390 - No 21 (2024年6月6日第390卷第21期)
https://www.nejm.org/toc/nejm/390/21

CORRESPONDENCE(通信)
1. 口服伊帕考潘治疗阵发性睡眠性血红蛋白尿症
Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria

(二)13 June 2024 - Volume 390 - No 22 (2024年6月13日第390卷第22期)
https://www.nejm.org/toc/nejm/390/22

CORRESPONDENCE(通信)
1. XBB.1.5疫苗针对奥密克戎亚型的持久性
Durability of XBB.1.5 Vaccines against Omicron Subvariants
2. 北美地区梅毒螺旋体对大环内酯类药物的近乎普遍抗性
Near-Universal Resistance to Macrolides of Treponema pallidum in North America
3. 布妥昔单抗治疗失败后,brigatinib在ALK阳性的ALCL中的使用
Brigatinib in ALK-Positive ALCL after Failure of Brentuximab Vedotin

(三)20 June 2024 - Volume 390 - No 23 (2024年6月20日第390卷第23期)
https://www.nejm.org/toc/nejm/390/23

ORIGINAL ARTICLES(原创文章)
1. 复发性弥漫大B细胞淋巴瘤的联合靶向治疗
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma
作者:Christopher Melani, Wyndham H. Wilson* (Lymphoid Malignancies Branch, USA)
2. 一种新型抗CD38单克隆抗体治疗免疫性血小板减少症
A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia
作者:Yunfei Chen, Yanmei Xu, Huiyuan Li, Ting Sun, Lei Zhang* (Chinese Academy of Medical Sciences and Peking Union Medical College, and the Tianjin Institutes of Health Science, China)
CORRESPONDENCE(通信)
1. 瑞博西利联合内分泌治疗在早期乳腺癌中的应用
Ribociclib plus Endocrine Therapy in Early Breast Cancer

(四)27 June 2024 - Volume 390 - No 24 (2024年6月27日第390卷第24期)
https://www.nejm.org/toc/nejm/390/24

ORIGINAL ARTICLES(原创文章)
1. 1至11岁患者中的嗜酸性食管炎的杜皮鲁单抗治疗
Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age
作者:Mirna Chehade* (Icahn School of Medicine at Mount Sinai, USA)
2. 贝那利珠单抗治疗嗜酸性食管炎的嗜酸性粒细胞耗竭
Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis
作者:Marc E. Rothenberg* (Cincinnati Children’s Hospital Medical Center, USA)
3. 重组人组织型纤溶酶原激活剂与阿替普酶治疗急性缺血性脑卒中的比较
Reteplase versus Alteplase for Acute Ischemic Stroke
作者:Shuya Li, Yongjun Wang* (China National Clinical Research Center for Neurologic Diseases, China; Beijing Tiantan Hospital, China)
4. 杜皮鲁单抗治疗伴有血液嗜酸性粒细胞证据的2型炎症慢性阻塞性肺病(COPD)
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation
作者:Surya P. Bhatt*, Klaus F. Rabe* (University of Alabama at Birmingham, USA; LungenClinic Grosshansdorf, Germany)
5. 布加替尼治疗NF2相关神经鞘瘤病伴进展性肿瘤
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
作者:Scott R. Plotkin* (Massachusetts General Hospital, USA)
EDITORIAL(社论)
1. 揭开嗜酸性食管炎发病机制中的元凶
Unmasking the Culprits in Eosinophilic Esophagitis Pathogenesis
作者:Benjamin L. Wright* (Phoenix Children’s Hospital, USA)
CORRESPONDENCE(通信)
1. UBTF串联重复AML对Menin抑制剂的响应与耐药性
Response and Resistance to Menin Inhibitor in UBTF–Tandem Duplication AML
2. 在胶质母细胞瘤中输注CARv3-TEAM-E T细胞
Infusion of CARv3-TEAM-E T Cells in Glioblastoma

四、美国医学会杂志 (2024年6月第331卷第21-24期)

(一)4 June 2024 -Volume 331 - No.21 (2024年6月4日第331卷第21期)
https://jamanetwork.com/journals/jama/issue/331/21

ORIGINAL INVESTIGATION(原创研究)
1. 普纳替尼与伊马替尼在一线费城染色体阳性急性淋巴细胞性白血病中的应用比较
Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
作者:Elias Jabbour (The University of Texas MD Anderson Cancer Center, USA)
MEDICAL NEWS IN BRIEF(医学新闻简讯)
1. 美国国家科学、工程和医学院的报告指出:COVID-19疫苗不会导致多种潜在的危害
National Academies Report: COVID-19 Vaccines Don’t Cause Many Potential Harms
作者:Emily Harris
2. 临床医生对耐药性疾病的新型抗生素处方不足
Clinicians Underprescribe Newer Antibiotics for Drug-Resistant Disease
作者:Emily Harris
3. 五联脑膜炎疫苗推出
Five-in-One Meningitis Vaccine Rolls Out
作者:Emily Harris
4. 停药计划与美国PPIs使用减少有关
Deprescribing Program Tied to Reductions in PPI Use in US
作者:Emily Harris

(二)11 June 2024 -Volume 331 - No.22 (2024年6月11日第331卷第22期)
https://jamanetwork.com/journals/jama/issue/331/22

JAMA INSIGHTS(JAMA洞见)
1. "预防接种"抵制错误信息
“Inoculation” to Resist Misinformation
作者:Sander van der Linden,  Jon Roozenbeek (University of Cambridge, UK)
MEDICAL NEWS & PERSPECTIVES(医学新闻与观点)
1. 联合疫苗对抗COVID-19、流感和其他呼吸道疾病可能很快面市
Combined Vaccines Against COVID-19, Flu, and Other Respiratory Illnesses Could Soon Be Available
作者:Rita Rubin
MEDICAL NEWS IN BRIEF(医学新闻简讯)
1. 抗精神病药物用于治疗痴呆与预期之外更严重的危害有关
Antipsychotics for Dementia Tied to More Serious Harms Than Expected
作者:Emily Harris

(三)18 June 2024 -Volume 331 - No.23(2024年6月18日第331卷第23期)
https://jamanetwork.com/journals/jama/issue/331/23

ORIGINAL INVESTIGATION (原创研究)
1. 磷虾油对膝关节骨关节炎的疗效:一项随机临床试验
Krill Oil for Knee Osteoarthritis: A Randomized Clinical Trial
作者:Laura L. Laslett (University of Tasmania, Australia)
2. 促进肺炎抗生素选择的管理提示:INSPIRE 随机临床试验
Stewardship Prompts to Improve Antibiotic Selection for Pneumonia: The INSPIRE Randomized Clinical Trial
作者:Shruti K. Gohil (University of California, Irvine School of Medicine, USA)
3. 促进尿路感染抗生素选择的管理提示:INSPIRE 随机临床试验
Stewardship Prompts to Improve Antibiotic Selection for Urinary Tract Infection: The INSPIRE Randomized Clinical Trial
作者:Shruti K. Gohil (University of California, Irvine School of Medicine, USA)
RESEARCH LETTER(研究简报)
1. 胰高血糖素样肽-1受体激动剂对青少年和年轻成人的配药,2020-2023
Dispensing of Glucagon-Like Peptide-1 Receptor Agonists to Adolescents and Young Adults, 2020-2023
作者:Joyce M. Lee (University of Michigan Medical School, USA)
2. 通胀削减法案取消成本分摊后,带状疱疹疫苗在医疗保险D部分的接种情况
Shingles Vaccination in Medicare Part D After Inflation Reduction Act Elimination of Cost Sharing
作者:Dima M. Qato (University of Southern California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, USA)
VIEWPOINT(观点)
1. 在阿尔茨海默病中通过降低淀粉样蛋白来传达伤害风险
Conveying Risks of Harm in Alzheimer Disease by Amyloid Lowering
作者:Madhav Thambisetty (National Institute on Aging, USA)
MEDICAL NEWS IN BRIEF(医学新闻简讯)
1. 授权用于保护有风险人群免受COVID-19侵害的单克隆抗体
Monoclonal Antibody Authorized to Protect At-Risk People From COVID-19
作者:Emily Harris
2. 微针疫苗贴片在儿童中产生免疫反应
Microneedle Vaccine Patches Generated Immune Response in Children
作者:Emily Harris
3. 血压药物与VA护理院中更多的骨折和跌倒有关
Blood Pressure Drugs Linked to More Fractures, Falls in VA Nursing Homes
作者:Emily Harris
4. 新药获准用于治疗尿路感染
New Drug for UTIs Gets the Greenlight
作者:Emily Harris
5. 较低剂量的Mpox疫苗安全有效
Lower Dose of Mpox Vaccine Was Safe, Effective
作者:Emily Harris
6. 单克隆抗体保护大多数儿童免受疟疾
Monoclonal Antibody Protected Majority of Children From Malaria
作者:Emily Harris

(四)25 June 2024 -Volume 331 - No.24(2024年6月25日第331卷第24期)
http://hhttps://jamanetwork.com/journals/jama/issue/331/24

ORIGINAL INVESTIGATION (原创研究)
1. 抗肿瘤药物临床试验的参与与生存获益:系统综述和荟萃分析
Survival Benefit Associated With Participation in Clinical Trials of Anticancer Drugs: A Systematic Review and Meta-Analysis
作者:Renata Iskander (McGill University, Canada)

五、自然:药物发现综述

June 2024  - Volume 23 - Issue 6(2024年6月第23卷第6期)
https://www.nature.com/nrd/volumes/23/issues/6

NEWS IN BRIEF(简讯)
1. 首创IL-15受体激动剂获FDA批准用于膀胱癌治疗
First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer
作者:Asher Mullard
2. CXCR4趋化因子拮抗剂首次获得FDA批准用于WHIM综合征
CXCR4 chemokine antagonist scores a first FDA approval for WHIM syndrome
作者:Asher Mullard
3. 双特异性抗体在类风湿关节炎中靶向B细胞
Bispecific antibody takes a BiTE out of B cells in rheumatoid arthritis
作者:Asher Mullard
BIOBUSINESS BRIEFS(生物商业简报)
1. 中国创新药在美国的发展
Development of Chinese innovative drugs in the USA
作者:Qianwei Ge, Liming Shao* (Fudan University, China)
RESEARCH HIGHLIGHT(研究亮点)
1. mRNA疗法为代谢紊乱带来希望
mRNA therapy shows promise for metabolic disorder
作者:Sarah Crunkhorn
2. RIPK3抑制剂预防严重流感感染中的肺部损伤
RIPK3 inhibitor prevents lung damage in severe influenza infection
作者:Joseph Willson
3. 靶向RAS新方法
New route to target RAS
作者:M. Teresa Villanueva
4. WRN抑制剂增加癌细胞的脆弱性
WRN inhibitors squeeze cancer cell vulnerability
作者:Katie Kingwell
5. 设计新型大环化合物药物
Designing novel macrocyclic drugs
作者:Sarah Crunkhorn
6. 靶向脓毒症中的ephrin信号传导
Targeting ephrin signalling in sepsis
作者:Sarah Crunkhorn
REVIEW ARTICLE(综述文章)
1. RNA基础药物的变革性突破框架
Frameworks for transformational breakthroughs in RNA-based medicines
作者:John R. Androsavich* (Ginkgo Bioworks, USA)
2. 靶向免疫原性细胞应激和死亡用于癌症治疗
Targeting immunogenic cell stress and death for cancer therapy
作者:Lorenzo Galluzzi* (Weill Cornell Medical College, USA)
3. 抗击疟疾、HIV和结核病中的抗菌素耐药性
Combating antimicrobial resistance in malaria, HIV and tuberculosis
作者:Maëlle Duffey, Didier Leroy* (The Global Antibiotic Research & Development Partnership, Switzerland; ICC, Switzerland)
COLLECTION(合集)
1. 2024年的交易概况:我们回顾了迄今为止2024年生物制药领域的交易情况,并介绍了正在开发制药行业下一项创新的活跃合作伙伴公司。
2. 疫苗领域的导航:通过我们的编辑特稿和公司展示,我们探索了疫苗领域的最新发展。

六、自然:免疫学综述 (2024年6月第24卷第6期)

June 2024 - Volume 24 -  Issue 6 (2024年6月第24卷第6期)
https://www.nature.com/nri/volumes/24/issues/6

REVIEW ARTICLE(综述文章)
1. 免疫疗法组合方法:机制、生物标志物和临床观察
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
作者:Lisa H. Butterfield* (University of California San Francisco, USA)
2. 1型糖尿病的免疫学
The immunology of type 1 diabetes
作者:Kevan C. Herold* (Yale University, USA)

七、柳叶刀:呼吸医学 (2024年第12卷第6期)

June 2024 - Volume 12 - Number 6 (2024年第12卷第6期)
https://www.thelancet.com/journals/lanres/issue/vol12no6/PIIS2213-2600(24)X0006-5#closeFullCover

COMMENT(评论)
1. 高剂量利福平治疗结核感染:潜力与陷阱
High-dose rifampicin to treat tuberculosis infection: potential and pitfalls
作者:Theresa S Ryckman* (Johns Hopkins School of Medicine, USA)
2. 口服皮质类固醇治疗急性学龄前喘息
Oral corticosteroids for acute preschool wheeze
作者:Heidi Makrinioti* (Massachusetts General Hospital, Harvard Medical School, USA)
3. MARS 2试验:胸膜间皮瘤中胸膜剥离术的未来
MARS 2 trial: the future of pleurectomy decortication in pleural mesothelioma
作者:Federica Grosso* (Azienda Ospedaliera Universitaria SS Antonio e Biagio e Cesare Arrigo, Italy)
4. 局部晚期非小细胞肺癌的系统性内镜分期:SEISMIC变化?
Systematic endoscopic staging of mediastinum in locally advanced NSCLC: a SEISMIC change?
作者:Angela Botticella, Cécile Le Pechoux* (Gustave Roussy, France)
ARTICLES(文章)
1. 高剂量、短疗程利福平与标准利福平用于结核病预防性治疗的比较:一项部分盲法、三臂、非劣效性、随机对照试验
High-dose, short-duration versus standard rifampicin for tuberculosis preventive treatment: a partially blinded, three-arm, non-inferiority, randomised, controlled trial
作者:Rovina Ruslami, Dick Menzies* (Universitas Padjadjaran, Indonesia; Research Institute of the McGill University Health Centre, Canada)
2. 口服皮质类固醇治疗急性学龄前喘息的疗效:一项系统综述和随机临床试验的个体参与者数据元分析
Efficacy of oral corticosteroids for acute preschool wheeze: a systematic review and individual participant data meta-analysis of randomised clinical trials
作者:Bohee Lee* (Centre for Population Health Sciences, Usher institute, University of Edinburgh, UK)

八、英国医学期刊 (2024年6月第385卷第8431-8434期)

(一)08 June 2024 - Volume 385 - Issue 8431(2024年6月8日第385卷第8431期)
https://www.bmj.com/content/385/8431

RESEARCH(研究)
1. 特瑞普利单抗联合化疗与安慰剂联合化疗作为晚期胃癌或胃食管结合部腺癌的一线治疗: RATIONALE-305 随机、双盲、3期临床试验
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
作者:Miao-Zhen Qiu, Rui-Hua Xu* (Chinese Academy of Medical Sciences, China; Sun Yat-Sen University, China)
2. 向初级保健医生发送有关65岁及以上患者抗生素处方的邮件反馈: 实用、因子随机对照试验
Mailed feedback to primary care physicians on antibiotic prescribing for patients aged 65 years and older: pragmatic, factorial randomised controlled trial
作者:Kevin L Schwartz* (Public Health Ontario, Canada)
3. 抗菌药物管理
Antimicrobial stewardship
作者:John H Powers III (George Washington University School of Medicine, USA)

(二)15 June 2024 - Volume 385 - Issue 8432(2024年6月15日第385卷第8432期)
https://www.bmj.com/content/385/8432

THIS WEEK(本周新闻
1. NICE对 tirzepatide 减重治疗的推荐可能会增加NHS的使用
NICE recommendations on tirzepatide for weight loss could increase NHS access
作者:Emma Wilkinson
RESEARCH(研究)
1. 冠状动脉搭桥术后的抗血小板治疗:随机DACAB试验的五年随访
Antiplatelet therapy after coronary artery bypass surgery: five year follow-up of randomised DACAB trial
作者:Yunpeng Zhu, Qiang Zhao* (Ruijin Hospital Shanghai Jiao Tong University School of Medicine, China)
2. 冠状动脉搭桥术后的双重抗血小板治疗
Dual antiplatelet therapy after coronary artery bypass surgery
作者:Sigrid Sandner* (Medical University of Vienna, Austria)
EDUCATION(教育)
1. 减少有反流症状的婴儿使用质子泵抑制剂
Reducing the use of proton pump inhibitors in infants with reflux symptoms
作者:Ketil Størdal* (University of Oslo, Norway)
2. 他汀类药物、血糖……及其他故事
Statins, blood glucose, . . . and other stories

(三)22 June 2024 - Volume 385 - Issue 8433(2024年6月22日第385卷第8433期)
https://www.bmj.com/content/385/8433

Research(研究)
1. 复发或转移性鼻咽癌患者一线化疗中使用白蛋白结合型紫杉醇、顺铂和卡培他滨与顺铂和吉西他滨的比较:随机3期临床试验
Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial
作者:Guo-Ying Liu, Yan-Qun Xiang* (Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of NPC Diagnosis and Therapy, China)
Education(教育)
1. 多重用药老年人的减药治疗
Deprescribing in older adults with polypharmacy
作者:Anna Hung* (Duke University School of Medicine, USA)
2. 抗抑郁药、胶质瘤……及其他故事
Antidepressants, glioma, . . . and other stories

(四)29 June 2024 - Volume 385 - Issue 8434(2024年6月29日第385卷第8434期)
https://www.bmj.com/content/385/8434

EDITORIALS (社论)
1. 分娩中背痛的无菌水注射
Sterile water injections for back pain in labour
作者:Giulia M Muraca* (McMaster University, Canada)
RESEARCH(研究)
1. 秋水仙碱在急性缺血性中风或短暂性缺血性发作患者中的应用(CHANCE-3):多中心、双盲、随机、安慰剂对照试验
Colchicine in patients with acute ischaemic stroke or transient ischaemic attack (CHANCE-3): multicentre, double blind, randomised, placebo controlled trial
作者:Jiejie Li, Yongjun Wang* (Beijing Tiantan Hospital, Capital Medical University, China)
2. SGLT-2抑制剂、GLP-1受体激动剂和DPP-4抑制剂与2型糖尿病患者高钾血症风险的关联:基于人群的队列研究
SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study
作者:Edouard L Fu, Elisabetta Patorno* (Brigham and Women’s Hospital and Harvard Medical School, USA)
ANALYSIS(分析)
1. 解决药品营销和推广过度的行为
Tackling the excesses of pharmaceutical marketing and promotion
作者:Ravi Gupta* (Johns Hopkins University School of Medicine, USA)
PRACTICE(实践)
1. 维生素B12缺乏:NICE指南摘要
Vitamin B12 deficiency: NICE guideline summary
作者:Toby Sands* (National Institute for Health and Care Excellence, UK)
2. 非特异性下背痛的镇痛
Analgesia for non-specific low back pain
作者:Caitlin M P Jones* (University of Sydney and Sydney Local Health District, Australia)

九、自然:医学 (2024年6月第30卷第6期)

June 2024 - Volume 30 - Issue 6(2024年6月第30卷第6期)
https://www.nature.com/nm/volumes/30/issues/6

News & Views(新闻和观点)
1. 新食物过敏治疗的炒作与希望
The hype and hope of new food allergy treatments
作者:Kirsten P. Perrett* (Murdoch Children’s Research Institute, Australia)
2. 利用AI提高药物安全性
Using AI to improve medication safety
作者:Johanna I. Westbrook* (Australian Institute of Health Innovation, Macquarie University, Australia)
3. 针对类风湿关节炎的BiTE疗法
BiTE therapy for rheumatoid arthritis
作者:Frances Humby* (Guy’s Hospital, UK)
Brief Communications(研究简报)
1. iPS细胞衍生的间充质基质细胞在急性类固醇抵抗性移植物抗宿主病中的两年安全性结果
Two-year safety outcomes of iPS cell-derived mesenchymal stromal cells in acute steroid-resistant graft-versus-host disease
作者:Kilian Kelly, John E. J. Rasko* (Cynata Therapeutics Limited, Australia; University of Sydney, Australia)
Articles(文章)
1. 大型语言模型用于预防在线药房的药物指示错误
Large language models for preventing medication direction errors in online pharmacies
作者:Cristobal Pais* ( Amazon, USA)
2. CD40配体拮抗剂dazodalibeb在Sjögren病中:一项随机、双盲、安慰剂对照、2期试验
CD40 ligand antagonist dazodalibep in Sjögren’s disease: a randomized, double-blinded, placebo-controlled, phase 2 trial
作者:E. William St. Clair* ( Duke University Department of Medicine, USA)
3. 针对难治性类风湿关节炎的双特异性T细胞引导疗法
Bispecific T cell engager therapy for refractory rheumatoid arthritis
作者:Laura Bucci, Melanie Hagen, Georg Schett* (Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Germany)
4. 新辅助nivolumab单独或联合relatlimab治疗可切除非小细胞肺癌:一项随机2期试验
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial
作者:Martin Schuler* (University Hospital Essen, Germany)
5. Senaparib作为晚期卵巢癌的一线维持治疗:一项随机3期试验
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial
作者:Xiaohua Wu*, Jihong Liu (Fudan University Shanghai Cancer Center, China; Sun Yat-sen University Cancer Center, China)
6. 培美加替尼在先前治疗过的携带激活FGFR1-FGFR3改变的实体瘤中的2期FIGHT-207篮式试验
Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial
作者:Jordi Rodón* (The University of Texas MD Anderson Cancer Center, USA)
7. 治疗前情绪困扰与非小细胞肺癌中免疫检查点抑制剂反应之间的关联
Association between pretreatment emotional distress and immune checkpoint inhibitor response in non-small-cell lung cancer
作者:Yue Zeng, Chun-Hong Hu, Yi-Zheng Li, Fang Wu* (The Second Xiangya Hospital, Central South University, China)
8. 轻度至中度阿尔茨海默病中p75神经营养因子受体调节:一项随机、安慰剂对照的2a期试验
p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial
作者:Hayley R. C. Shanks*, Taylor W. Schmitz* (Western University, Canada)

十、世界精神病学 (2024年第23卷第2期)

2024 - Volume 23 - Issue 2(2024年第23卷第2期)
https://onlinelibrary.wiley.com/toc/20515545/2024/23/2

Research Report(研究报告)
1. 抗抑郁药、抗精神病药及其组合在精神病性抑郁维持治疗中的真实世界有效性。来自两个全国队列的个体内分析的证据
Real-world effectiveness of antidepressants, antipsychotics and their combinations in the maintenance treatment of psychotic depression. Evidence from within-subject analyses of two nationwide cohorts
作者:Heidi Taipale (University of Eastern Finland, Niuvanniemi Hospital Finland)
Letter to the Editor(致编辑的信)
1. 监狱环境中治疗药物使用障碍:联合国毒品和犯罪问题办公室-世界卫生组织非正式科学网络、联合国麻醉品委员会声明
Treatment of substance use disorders in prison settings: statement by the UNODC-WHO Informal Scientific Network, UN Commission on Narcotic Drugs
作者:Nora D. Volkow (National Institute on Drug Abuse, USA)
2. 双相障碍中的药物治疗和缺失:一项基于全国注册的研究报告
Medication use and sickness absence from work in bipolar disorder: a nationwide register-based study
作者:Minna Holm (Finnish Institute for Health and Welfare, Finland)
3. 通过冥想和迷幻剂调节自我参照加工:自我超越的科学调查在临床上是否相关?
Modulating self-referential processing through meditation and psychedelics: is scientific investigation of self-transcendence clinically relevant?
作者:Matthew D. Sacchet (Massachusetts General Hospital, Harvard Medical School, USA)
4. 将专家认可的认知康复干预措施转化为治疗药物使用障碍的临床应用
Clinical translation of expert-endorsed cognitive rehabilitation interventions for substance use disorders
作者:Antonio Verdejo-Garcia (Monash University, Australia)

网友评论